SIGMA-SYSTEMS
2.5.2017 11:02:08 CEST | Business Wire | Press release
Sigma Systems, a global leader in catalog-driven software, has appointed Catherine Michel as Chief Technology Officer (CTO).
Michel previously served as Chief Strategy Officer (CSO) on Sigma’s leadership team, and currently sits on the TM Forum Executive Committee, has been named as one of the most powerful people in the telecoms industry by Global Telecoms Business, and is a public advocate and mentor for women in telco and IT. As Sigma’s Chief Technology Officer, Catherine is responsible for the company's product portfolio and strategy.
“Catherine is a globally respected member of the IT and communications technology community, and we are very fortunate to have her on the Sigma team. She has an excellent track record of innovation within the software development arena and is a highly strategic thinker. Catherine has been vital in driving Sigma’s product portfolio forward, and will continue to do so in her new role in the coming months and years. Catherine is a key spokesperson for the company at events and technology forums across the globe,” said Tim Spencer, Sigma’s President and CEO.
Prior to her roles at Sigma, Michel was the founder and CTO of Tribold, where she was the principal architect of the company's products and solutions portfolio. Tribold was acquired by Sigma in 2013. Prior to co-founding Tribold, she was a senior executive in Accenture's Communications and High Tech practice, devising and delivering business strategy and large-scale B/OSS solutions globally.
“Sigma is on the cutting edge of delivering technology solutions that enable operators to truly transform into agile digital service providers,” observed Michel. “I continue to be excited about the position we’ve achieved in the market and the opportunities ahead of us.”
Catherine will be speaking at TM Forum Live! in Nice with Sigma customer Windstream. The joint presentation will outline how Windstream developed, governed and executed a widespread digital transformation program in parallel with a major acquisition and SDN deployment. As a key strategic partner, Sigma is supporting Windstream’s transition to an agile delivery organization with the adoption of catalog-driven Agile B/OSS. Sigma’s portfolio is designed to support CSPs like Windstream to embrace digital innovation and enable the rapid launch and fulfilment of new products and services without entirely dismantling existing legacy systems.
Presentation Details:
May 15th
, 11:15am
TM Forum
Live!
Palais des Congrès Acropolis, Nice, France
About Sigma Systems (
sigma-systems.com
or Twitter @SigmaSystems)
Sigma Systems is a global leader in
catalog-driven software solutions for communications, media, and
high-tech companies. It serves over 80 customers in 40 countries with
its award-winning products.
The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management and Provisioning products, which can be deployed in the cloud or on-premise. Sigma utilizes an agile approach to implementing its B/OSS products for its customers.
Sigma has offices in North and South America, Europe and Asia, with technology and integration partners in over 100 countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170502005185/en/
Contact:
Sigma Systems
Noor Manji, 416-943-9696
Manager, Corporate
Communications
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom